Lucid Diagnostics ( (LUCD) ) has provided an update.
Lucid Diagnostics reported a 20% increase in revenue for its EsoGuard esophageal DNA test in the third quarter of 2024, with significant milestones achieved, including expanded direct contracting initiatives and a complete clinical evidence package for Medicare coverage submission. The company also announced a peer-reviewed publication for its clinical validation study and received a Notice of Allowance for a key patent. Financially, Lucid secured $21.75 million from investors to bolster its cash reserves, despite a net loss of $12.4 million for the quarter.
For detailed information about LUCD stock, go to TipRanks’ Stock Analysis page.